Non-small Cell Lung Cancer Therapeutics Market by Cancer Type (Adenocarcinoma, Large Cell Carcinoma, Squamous Cell Carcinoma), Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Folate Antimetabolites), Distribution Channel - Gl

Non-small Cell Lung Cancer Therapeutics Market by Cancer Type (Adenocarcinoma, Large Cell Carcinoma, Squamous Cell Carcinoma), Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Folate Antimetabolites), Distribution Channel - Global Forecast 2024-2030


The Non-small Cell Lung Cancer Therapeutics Market size was estimated at USD 16.66 billion in 2023 and expected to reach USD 17.94 billion in 2024, at a CAGR 7.76% to reach USD 28.13 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Non-small Cell Lung Cancer Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Non-small Cell Lung Cancer Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Non-small Cell Lung Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bristol Myers Squibb Company, C.H. Boehringer Sohn AG & Ko. KG, Celgene Corporation, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Non-small Cell Lung Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Cancer Type

Adenocarcinoma

Large Cell Carcinoma

Squamous Cell Carcinoma
Drug Class

Angiogenesis Inhibitor

Epidermal Growth Factor Receptor Blocker

Folate Antimetabolites

Kinase Inhibitor

Microtubule Stabilizer

PD-1/ PD-L1 Inhibitor
Distribution Channel

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Non-small Cell Lung Cancer Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Non-small Cell Lung Cancer Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Non-small Cell Lung Cancer Therapeutics Market?
4. What is the market share of the leading vendors in the Non-small Cell Lung Cancer Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Non-small Cell Lung Cancer Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Non-small Cell Lung Cancer Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of Non-small Cell Lung Cancer (NSCLC) across the globe due to increasing air pollution and smoking habits
5.1.1.2. Presence of a strong pipeline for NSCLC therapeutics
5.1.2. Restraints
5.1.2.1. High cost and lack of availability of the drug
5.1.3. Opportunities
5.1.3.1. Introduction of new targeted therapies and treatments
5.1.3.2. Adoption of advanced therapeutics in the developing countries
5.1.4. Challenges
5.1.4.1. Capital intensive treatment and procedures
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Non-small Cell Lung Cancer Therapeutics Market, by Cancer Type
6.1. Introduction
6.2. Adenocarcinoma
6.3. Large Cell Carcinoma
6.4. Squamous Cell Carcinoma
7. Non-small Cell Lung Cancer Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Angiogenesis Inhibitor
7.3. Epidermal Growth Factor Receptor Blocker
7.4. Folate Antimetabolites
7.5. Kinase Inhibitor
7.6. Microtubule Stabilizer
7.7. PD-1/ PD-L1 Inhibitor
8. Non-small Cell Lung Cancer Therapeutics Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Non-small Cell Lung Cancer Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Astellas Pharma Inc.
13.1.2. AstraZeneca PLC
13.1.3. Bristol Myers Squibb Company
13.1.4. C.H. Boehringer Sohn AG & Ko. KG
13.1.5. Celgene Corporation
13.1.6. Eisai Co., Ltd.
13.1.7. Eli Lilly and Company
13.1.8. F. Hoffmann-La Roche Ltd.
13.1.9. GlaxoSmithKline PLC
13.1.10. Merck KGaA
13.1.11. Novartis International AG
13.1.12. Pfizer Inc.
13.1.13. Sanofi S.A.
13.1.14. Takeda Pharmaceutical Company Limited
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET DYNAMICS
FIGURE 7. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
FIGURE 8. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings